Melek Karakurt Eryilmaz
Overview
Explore the profile of Melek Karakurt Eryilmaz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kocak M, Araz M, Findik S, Demirkiran A, Korkmaz M, Karakurt Eryilmaz M, et al.
Biomol Biomed
. 2025 Jan;
PMID: 39869369
The cysteine-rich epidermal growth factor ligand domain 2 protein (CRELD2) is associated with pathways that regulate epithelial-to-mesenchymal transition, a critical process driving cancer metastasis. This study aimed to determine the...
2.
Ozyurt N, Alkan A, Gulbagci B, Seyyar M, Asik E, Sahbazlar M, et al.
Sci Rep
. 2024 Oct;
14(1):23556.
PMID: 39384975
The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early...
3.
Caglayan D, Kocak M, Geredeli C, Atci M, Tatli A, Sezgin Goksu S, et al.
Future Oncol
. 2024 Sep;
20(38):3099-3105.
PMID: 39316555
Endocrine therapy (ET) plus cyclin-dependent kinase (CDK) 4/6 inhibitors is a standard treatment for hormone receptor (HR) positive HER-2-negative metastatic breast cancer patients. In this study, we aimed to investigate...
4.
Yildiz O, Gurbuz A, Karakurt Eryilmaz M, Araz M, Aykut T, Sahin O, et al.
J Oncol Pharm Pract
. 2024 Sep;
31(1):168-171.
PMID: 39311109
Introduction: Ado-trastuzumab emtansine (T-DM1) is employed in the treatment of patients with HER2-positive breast cancer. The most common side effects are fatigue, diarrhoea, anaemia, transaminase elevation and drug-induced thrombocytopenia. This...
5.
Araz M, Beypinar I, Inci F, Koral L, Kocak M, Korkmaz M, et al.
J Oncol Pharm Pract
. 2024 Aug;
:10781552241279537.
PMID: 39196659
Introduction: We compared the efficacy of first-generation granisetron and second-generation palonosetron in triplet anti-emetic prophylaxis in patients with non-small cell lung cancer (NSCLC) receiving cisplatin-based high emetogenic chemotherapy (HEC). Methods:...
6.
Gurbuz A, Karakurt Eryilmaz M, Yildiz O, Kaya B, Araz M, Artac M
J Oncol Pharm Pract
. 2024 Aug;
31(1):160-163.
PMID: 39140806
Introduction: Lorlatinib is a potent third-generation anaplastic lymphoma kinase/c-ros oncogene 1 (ALK)/ROS1 oral tyrosine kinase inhibitor that has broad coverage of acquired resistance mutations and is currently indicated for the...
7.
Ilhan Y, Ucar G, Baser M, Guzel H, Efil S, Demir B, et al.
Expert Opin Pharmacother
. 2024 Aug;
25(11):1555-1563.
PMID: 39115275
Objectives: We aimed to evaluate the efficacy and safety of granulocyte-colony stimulating factor (G-CSF) prophylaxis during chemoimmunotherapy with carboplatin plus etoposide and atezolizumab in extensive-stage small cell lung cancer (ES-SCLC)....
8.
Gurbuz A, Karakurt Eryilmaz M, Yildiz O, Kilinc F, Araz M, Artac M
Strahlenther Onkol
. 2024 Jul;
200(11):986-990.
PMID: 38995367
Introduction: Bloom syndrome (BS) is a rare autosomal recessive disorder caused by a loss-of-function mutation in the BLM gene encoding an RecQ helicase involved in DNA repair and maintenance of...
9.
Tasci E, Kutlu Y, Olmez O, Mutlu A, Gundogdu Y, Seyyar M, et al.
Expert Opin Pharmacother
. 2024 Apr;
25(4):477-484.
PMID: 38568074
Background: Triple negative breast cancer (TNBC) is characterized by high rates of recurrence, especially in patients with residual disease after neoadjuvant chemotherapy (NAC). Capecitabine is being used as standard adjuvant...
10.
Korkmaz M, Karakurt Eryilmaz M, Kocak M, Er M, Hendem E, Demirkiran A, et al.
Eur J Clin Pharmacol
. 2024 Mar;
80(6):941-947.
PMID: 38478093
Purpose: Vascular endothelial growth factor (VEGF) inhibition is one of the cornerstones of treatment in the treatment of metastatic renal cell carcinoma (mRCC). Since RCC is a disease of advanced...